Dorsey Asset Management LLC Has $72.80 Million Holdings in Enovis Corporation $ENOV

Dorsey Asset Management LLC cut its holdings in Enovis Corporation (NYSE:ENOV) by 6.0% in the third quarter, HoldingsChannel reports. The firm owned 2,399,322 shares of the company’s stock after selling 153,858 shares during the quarter. Enovis accounts for 6.5% of Dorsey Asset Management LLC’s portfolio, making the stock its 9th largest position. Dorsey Asset Management LLC’s holdings in Enovis were worth $72,795,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ENOV. Brevan Howard Capital Management LP lifted its position in Enovis by 5.8% during the third quarter. Brevan Howard Capital Management LP now owns 46,636 shares of the company’s stock valued at $1,415,000 after purchasing an additional 2,540 shares during the last quarter. Aquatic Capital Management LLC increased its holdings in shares of Enovis by 28.7% in the 3rd quarter. Aquatic Capital Management LLC now owns 52,633 shares of the company’s stock worth $1,597,000 after buying an additional 11,722 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Enovis during the 3rd quarter valued at about $553,000. Creative Planning bought a new position in shares of Enovis in the 3rd quarter valued at about $274,000. Finally, Rubric Capital Management LP bought a new position in shares of Enovis in the 3rd quarter valued at about $83,435,000. Institutional investors own 98.45% of the company’s stock.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert bought 1,000 shares of the company’s stock in a transaction on Friday, February 27th. The shares were bought at an average cost of $25.50 per share, for a total transaction of $25,500.00. Following the acquisition, the insider directly owned 43,640 shares in the company, valued at approximately $1,112,820. The trade was a 2.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have bought 4,000 shares of company stock valued at $98,243 over the last ninety days. 2.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ENOV has been the topic of several analyst reports. Evercore reissued an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Wall Street Zen upgraded Enovis from a “hold” rating to a “buy” rating in a report on Saturday. Needham & Company LLC boosted their target price on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Canaccord Genuity Group decreased their price target on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Finally, Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.43.

Enovis Trading Down 1.7%

ENOV opened at $22.99 on Friday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The stock’s fifty day moving average is $23.81 and its two-hundred day moving average is $27.80. The company has a market capitalization of $1.32 billion, a P/E ratio of -1.11 and a beta of 1.46. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $40.69.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The business had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. During the same period in the prior year, the business earned $0.98 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.